Logo

Investment Bank Cuts Illumina Shares Though Says Genotyping Tech 'Best in Class'

Sep 18, 2006

NEW YORK (GenomeWeb News) — Investment bank Cowen & Co. today downgraded shares of Illumina to "Neutral" from "Outperform."
 
Reuters today reported that Cowen said the shares "appear reasonably valued, noting the firm's shares were up 154 percent year-to-date."
 
Reuters reported that the brokerage said "many investors agree with its view that Illumina's high-throughput genotyping technology is best in class."

Breaking News
The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.